Abstract
In the last five years several consensus guidelines for blood product usage have appeared in the literature [1–13]. The guidelines can be used to form the framework from which individual institutions can design criteria for the appropriate use of blood and blood components, while taking into account the preferences of physicians at the institution. Some aspects of these guidelines are generally accepted by most physicians. Reflecting the ever-evolving nature of transfusion practice, however, some of the guidelines which are more controversial are less widely accepted. Establishing a set of audit criteria for blood component usage should be considered as just the first step in improving the quality of care. To be truly effective, audits must be accompanied by feedback to the clinicians. Audits and guidelines should also reflect continued awareness of the changes taking place in clinical transfusion practice. We will discuss some of these published guidelines, playing particular attention to the portions which are either controversial or currently in evolution. Additionally, we will focus on the approach taken by our tertiary academic medical center and some of our experiences with audits and our attempts to control blood product utilization.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Consensus conference. Perioperative red cell transfusion. JAMA 1988;260:2700–03.
Welch HG, Meehan KR, Goodnough LT. Prudent strategies for elective red blood cell transfusion. Ann Intern Med 1992;116:393–402.
Audet AM, Goudnough LT. Practice strategies for elective red blood cell transfusion. Ann Intern Med 1992;116:404–6.
Halsey PB, Lave JR, Kapoor WN. The necessary and the unnecessary transfusion: A critical review of reported appropriateness rates and criteria for red cell transfusions. Transfusion 1994;34:110–15.
Stehling L, Luban NLC, Anderson KC, et al. Guidelines for blood utilization review. Transfusion 1994;34:438–48.
Lundberg GD (ed). Practice parameter for the use of fresh-frozen plasma, cryoprecipitate, and platelets. JAMA 1994;271:777–81.
Consensus conference. Fresh-frozen plasma: Indications and risks. JAMA 1985;253: 551–53.
Metz J, McGrath KM, Copperchini ML, et al. Appropriateness of transfusions of red cells, platelets and fresh frozen plasma: An audit in a tertiary care teaching hospital. Med J Aust 1995;162:572–77.
Blanchette VA, Hume HA, Levy GJ, Luban NLC, Strauss RG. Guidelines for auditing pediatric blood transfusion practices. AJDC 1991;145:787–96.
National blood resource education program expert panel on the indications for the use of red blood cells, platelets and fresh frozen plasma. Transfusion alert: Indications for the use of red blood cells, platelets and fresh frozen plasma. Aug 1993. National Institutes of Health (NIH Publication No. 93–2974a).
Mintz PD. Quality assessment and improvement of transfusion practices. Hemat/Oncol Clin Nrth Amer 1995;9:219–32.
American Association of Blood Banks Transfusion Practices Quality Assurance Committee, 1992–1993 Committee. Guidelines for blood utilization review. Bethesda, MD, American Association of Blood Banks, 1994.
Consensus conference. Platelet transfusion therapy. JAMA 1987;257:1777–80.
Rustad H, Myhre E. Surgery during anticoagulant treatment. Acta Med Scand 1963;173:115–19.
Ewe K. Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. Digestive Diseases and Sciences 1981;26:388–93.
Burns ER, Goldberg SN, Wenz B. Paradoxical effect of multiple mild coagulation factor deficiencies on the prothrombin time and activated partial thromboplastin time. Am J Clin pathol 1993;100:94–98.
McVay PA, Toy PTCY. Lack of increased bleeding after paracentesis and thoracentesis in patients with mild coagulation abnormalities. Transfusion 1991;31:164–71.
Counts RB, Haisch C, Simon TL, Maxwell NG, Heimbach DM, Carrico CJ. Hemostasis in massively transfused trauma patients. Ann Surg 1979;190:91–99.
Gaydos LA, Freireich EJ, Mantel N. The quantitative relation between platelet count and hemorrhage in patients with acute leukaemia. N Engl J Med 1962;266:905–9.
Beutler E. Platelet transfusions: The 20,000/μL trigger. Blood 1993;81:1411–13.
Gmur J, Burger J, Schanz U, Fehr J, Schaffner A. Safety of stringent prophylactic platelet transfusion policy for patients with acute leukemia. Lancet 1991;338:1223–26.
Pisciotto PT, Benson K, Hume H, et al. Prophylactic versus therapeutic platelet transfusion practices in hematology and/or oncology patients. Transfusion 1995;35:498–502.
Strauss RG. Granulocyte transfusion therapy. Hemat/Oncol Clin Nrth Amer 1994;8:1159–66.
Strauss RG. Therapeutic granulocyte transfusions in 1993. Blood 1993;81:1675–78.
Huestis DW, Glasser L. The neutrophil in transfusion medicine. Transfusion 1993;34:630–46.
Bensinger WI, Price TH, Dale DC, et al. The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood 1993;81:1883–88.
Klein H (ed). Standards for blood banks and transfusion services. 16th ed. American Association of Blood Banks, Bethesda, MD, 1994:13.
Hillyer CD, Emmens RK, Zago-Novaretti M, Berkman EM. Methods for the reduction of transfusion-transmitted cytomegalovirus infection: Filtration versus the use of seronegative donor units. Transfusion 1994;34:929–34.
Preiksaitis JK. Indications for the use of cytomegalovirus-seronegative blood products. Trans Med Rev 1991;5:1–17.
Bowden RA. Transfusion-transmitted cytomegalovirus infection. Hemat/Oncol Clin Nrth Amer 1995;9:155–66.
Bowden RA, Slichter SJ, Sayers M, et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995;86:3598–603.
Zhang LJ, Hanff P, Rutherford C, Churchill WH, Crumpacker CS. Detection of human cytomegalovirus DNA, RNA, and antibody in normal donor blood. J Infect Dis 1995;171:1002–6.
Smith KL, Cobain T, Dunsten RA. Removal of cytomegalovirus DNA from donor blood by filtration. Br J Haematol 1993;83:640–42.
Leitman SF, Holland PV. Irradiation of blood products: Indications and guidelines. Transfusion 1985;25:293–300.
Huestis DA, Bove JR, Case J. Practical Blood Transfusion. Boston: Little, Brown and Company, 1988.
Center for Biologics Evaluation and Research; FDA. Recommendations regarding license amendments and procedures for gamma irradiation of blood products. Rockville, MD, July 22, 1993.
Sola MA, Espana A, Redondo P, et al. Transfusion-associated acute graft-versus-host disease in a heart transplant recipient. Brit J Derm 1995;132:626–30.
Lane TA. Leukocyte reduction of cellular blood components. Arch Pathol Lab Med 1994;118:392–404.
Menitove JE, McElligott MC, Aster RH. Febrile transfusion reactions: What blood component should be given next? Vox Sang 1982;42:318–21.
Stack G, Snyder EL. Cytokine generation in stored platelet concentrates. Transfusion 1994;34:20–25.
Heddle NM, Klama L, Singer J, et al. The role of the plasma from platelet concentrates in transfusion reactions. N Engl J Med 1994;331:625–28.
Heddle NM, Blajchman MA. The leukodepletion of cellular blood products in the prevention of HLA-alloimmunization and refractoriness to allogeneic platelet transfusion. Blood 1995;85:603–6.
De Wolf JThM, Westerterp A, Smit Sibinga CTh, Halie MR. Prestorage leukocyte depletion is not necessarily required for the prevention of refractoriness to platelet transfusion. Blood 1995;86:3263.
Nevalainen DE, Lloyd HL. ISO-9000 quality standards: A model for blood banking? Transfusion 1995;35:521–24.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Kluwer Academic Publishers
About this chapter
Cite this chapter
Petrides, M., Snyder, E.L. (1996). Transfusion Policies and Clinical Practice in a Tertiary Academic Medical Center: Role of Protocols and Documentation. In: Sibinga, C.T.S., Das, P.C., Snyder, E.L. (eds) Trigger Factors in Transfusion Medicine. Developments in Hematology and Immunology, vol 31. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1287-1_13
Download citation
DOI: https://doi.org/10.1007/978-1-4613-1287-1_13
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-8550-2
Online ISBN: 978-1-4613-1287-1
eBook Packages: Springer Book Archive